Background {#Sec1}
==========

Prostate cancer is the most frequent cancer and the third leading cause of death among men in developed countries \[[@CR1]\]. Approximately one third to one half of patients suffer from biochemical relapse (BCR) within 5--10 years after primary curative prostatectomy or radiotherapy (RT) \[[@CR2]--[@CR4]\]. Salvage radiotherapy (SRT) is recommended in patients treated with radical prostatectomy who experience BCR without distant metastases \[[@CR5], [@CR6]\]. The most evident benefit of SRT has been found in BCR patients with low PSA levels (≤0.5 ng/ml) \[[@CR7], [@CR8]\]. Stephenson et al. reported a 6-year post-SRT progression-free probability of 48 % in patients with a PSA \<0.5 ng/ml compared with 40, 28, and 18 % in patients with PSA levels of 0.51--1 ng/ml, 1.01--1.5 ng/ml, and \>1.5 ng/ml, respectively \[[@CR9]\]. The extent of SRT (prostate bed vs. prostate bed and pelvic lymph nodes) is still a matter of controversy \[[@CR5]\]. Goldner et al. reported a significantly increased risk for biochemical failure after SRT in patients with a risk of lymph node involvement \>15 % according to the Roach formula and SRT limited to the prostate bed \[[@CR10]\]. However, automatic inclusion of radiation of the pelvic lymph nodes as part of SRT is currently not recommended \[[@CR5], [@CR6]\].

The role of pretherapeutic imaging in SRT planning has not been definitively assessed. The relevance of conventional imaging (e.g., computed tomography, bone scintigraphy) is low due to limited sensitivity in patients with low PSA values \[[@CR11], [@CR12]\]. Molecular imaging using choline PET/CT has recently been widely used in patients with BCR. ^11^C-choline PET/CT proved to be sensitive in patients with a PSA level \>1 ng/ml and is often used if imaging results are considered relevant for treatment planning \[[@CR5]\], e.g., for metastasis-directed therapy in oligometastatic disease \[[@CR13]\]. However, the detection rates and accuracy of choline PET/CT are limited \[[@CR14], [@CR15]\]. Krause et al. reported a detection rate of \<50 % in patients with a PSA level ≤2 ng/ml \[[@CR16]\]. A PSA level of 1.16 ng/ml was found to be an optimal cutoff value for prediction of a positive choline PET/CT scan \[[@CR17]\]. The American Society for Radiation Oncology (ASTRO) guidelines stated that "improved imaging techniques would help to better define appropriate therapies" \[[@CR6]\].

The recent introduction of PET ligands to image the expression of the prostate-specific membrane antigen (PSMA) appears to be revolutionizing prostate cancer imaging and therapy \[[@CR18], [@CR19]\]. Numerous studies have reported that ^68^Ga-labeled peptide ligands targeting the cell surface protein PSMA are more specific and also highly sensitive \[[@CR20]--[@CR25]\]. Detection rates of 74.2--89.5 % have been reported in patients with BCR even in the presence of low PSA levels (\<1 ng/ml) \[[@CR20]--[@CR24]\]. Van Leeuwen et al. found in a cohort of 70 patients with BCR (PSA level \<1.0 ng/ml) and considered for SRT PSMA-positive lesions in 54 % of the patients \[[@CR26]\]. A recently published meta-analysis summarized the available studies and reported in patients with BCR an overall positivity rate of 76 % \[[@CR27]\]. However, only limited data are available regarding the impact of ^68^Ga-PSMA PET/CT on SRT planning \[[@CR28]--[@CR30]\]. Change of treatment based on the ^68^Ga-PSMA PET/CT findings has been reported in 50.8 and 53.7 % of patients, but these cohorts included primary disease and BCR \[[@CR29], [@CR30]\]. Dewes et al. found a change of TNM stage in 53.3 % and a change in RT concept in 33.3 % of cases prior to initial curative RT \[[@CR28]\]. Patient cohorts were heterogeneous, and only very limited data are available on patient outcome in ^68^Ga-PSMA PET/CT-guided RT \[[@CR31]\]. The aim of this study was to evaluate the impact of ^68^Ga-PSMA PET/CT on treatment decision-making prior to SRT and particularly on the patient outcome.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Between September 2014 and May 2016, 45 prostate cancer patients with persisting PSA (16/45; 35.6 %) or BCR (29/45; 64.4 %) after radical prostatectomy were referred for a ^68^Ga-PSMA PET/CT prior to SRT (Table [1](#Tab1){ref-type="table"}) to excluded distant metastases. All but one were initially treated with lymph node dissection in addition to prostatectomy. All patients were hormone-naïve at the time of imaging. The mean patient age at the time of initial diagnosis was 63.0 ± 6.9 years (range 46.7--78.8 years) and, at the time of imaging, 68.8 ± 7.0 years (range 52.3--80.0 years). ^68^Ga-PSMA PET/CT was performed 5.7 ± 5.3 years (range 0.15--20.9 years) after initial curative treatment. The mean serum PSA level at the time of ^68^Ga-PSMA PET/CT was 1.30 ± 2.06 ng/ml (range 0.10--11.22 ng/ml; median 0.67 ng/ml). The mean PSA doubling time was 7.4 ± 8.0 months (range 0.0--31.5 months; median 4.8 months).Table 1Patient characteristicsNo. of patients (%)Mean (range) (median)Age at initial diagnosis (years)63.0 ± 6.9 (46.7--78.8)Initial Gleason score7 ± 1 (4--9)Initial PSA level (ng/ml)22.46 ± 55.48 (1.85--378.2) (11.2)Pathologic tumor stage T2N023 (51) T2N11 (2) T2Nx1 (2) T3N08 (18) T3N19 (20) ypT3N02 (4) ypT3N11 (2)R status R030 (67) R114 (31) Rx1 (2)D'Amico risk classification High risk39 (87) Intermediate risk4 (9) Low risk2 (4)

Due to the retrospective design of this study, a need for formal review was waived by the local ethics committee.

^68^Ga-PSMA PET/CT {#Sec4}
------------------

Images were acquired on a Biograph mCT 64 (Siemens Medical Solutions, Germany). All patients received EuK-Sub-kf(3-iodo-y)-^68^Ga-DOTAGA (^68^Ga-PSMA I&T). ^68^Ga-PSMA I&T was synthesized as previously described \[[@CR32], [@CR33]\]. 141 ± 19 MBq (range 97--184 MBq) ^68^Ga-PSMA I&T was injected intravenously in combination with 10--20 mg of furosemide to improve image quality. Images were acquired 60 min after injection from the base of the skull to the proximal thighs (2--3 min/bed position). In 25/45 (55.6 %) patients, contrast-enhanced CT was acquired and also used for attenuation correction. Of the 45 patients, 20 (44.4 %) underwent a low-dose CT protocol due to available contrast-enhanced imaging within 4 weeks prior to ^68^Ga-PSMA PET/CT. Image reconstruction was performed as previously described \[[@CR22]\]. PET/CT images were visually analyzed by experienced nuclear medicine physicians and radiologists. In PET, any focal uptake that was not physiological and was higher than the surrounding background was considered suspicious. For PET-positive lesions, the SUV~max~ was measured. For CT image analysis, morphological criteria for malignancy (e.g., small axis diameter of 10 mm for lymph nodes or osteoblastic lesions for bone metastases) were used.

Treatment decision {#Sec5}
------------------

All patients were primarily planned to receive SRT of the prostate bed. For the final treatment decision, results of ^68^Ga-PSMA PET/CT were taken into account by an interdisciplinary panel of radiation oncologists, urologists, radiologists, and nuclear medicine physicians. If oligometastatic disease (≤5 metastatic lesions in ≤3 organs) was detected, treatment was changed to high-dose RT of the lesions according to the institutional therapeutic concept, similar to the approach reported in previous publications \[[@CR13], [@CR29], [@CR31], [@CR34]\]. In the presence of more than five metastases, the panel recommended systemic treatment with androgen deprivation therapy (ADT).

Salvage radiotherapy {#Sec6}
--------------------

Image-guided intensity-modulated radiotherapy (IMRT) was performed in all patients receiving RT. Patients were treated on an Elekta Synergy® accelerator using 6-MV photons. SRT was performed in about 7 weeks in five fractions per week. SRT planning was based on CT scans with 3-mm slice thickness, empty rectum, and full bladder. Radiotherapy was carried out in the supine position with daily image guidance with megavoltage cone beam CT (CBCT).

In patients with negative ^68^Ga-PSMA PET/CT, standard RT up to a total dose of 66--70 Gy using a simultaneously integrated boost (SIB) and sequential boost was administered to the prostate bed. Clinical target volume (CTV~prostate\ bed~) was defined according to the guidelines as described by Poortmans et al. \[[@CR35]\]. Pathological tracer uptake in the prostate bed without any morphological correlate on CT resulted in an extension of the CTV~prostate\ bed~ to this PET-positive area. If a morphological local recurrence was detected on CT, an additional dose escalation up to 76 Gy was administered to the malignant tissue. A 10-mm margin was used to define the planning target volume (PTV) of the prostate bed (PTV~prostate\ bed~). For the PTV~SIB\ prostate\ bed~, the margin was reduced to 5 mm.

When lymph node metastases (LNMs) were evident on CT and/or pathological tracer uptake was seen on PET, an additional CTV~LN~ was defined with a 5-mm margin around the vessels, including the external iliac, internal iliac, and obturator nodes, to a cranial border at the level of the promontory. In the case of pathological retroperitoneal LNMs, the cranial border was extended to a maximum of renal vessels. An additional 5-mm margin was used to define PTV~LN~. Patients received irradiation of the PTV~LN~ at daily doses of 1.8 Gy up to a total of 50.4 Gy. To define the PTV~SIB\ LN~ for involved nodes, we added a 10-mm margin around the tracer uptake. LNMs detected on ^68^Ga-PSMA PET/CT received a daily SIB of 2 Gy up to 56.0 Gy and a sequential boost up to 60.0--66.0 Gy. The dose was limited by adjacent anatomic structures, e.g., bowel. In accordance with the oligometastatic concept, bone lesions were also irradiated. A total dose of 66.0 Gy was administered. Clinical examination during radiotherapy was done once to twice weekly. Acute side effects were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE 4.0). After the end of SRT, patients were followed up by measurement of serum PSA values to assess the biochemical response to treatment.

Statistics {#Sec7}
----------

Descriptive analysis was performed by calculating the mean, standard deviation (SD), range, and median. PSA doubling time was calculated as previously described \[[@CR22]\]. Two-sided two-sample *t* test was used to evaluate changes in PSA levels following therapy, compared with pretherapy levels (significance level *α* = 5 %). Statistical analyses were conducted with Excel statistics software (Excel 2010, Microsoft, WA, USA).

Results {#Sec8}
=======

^68^Ga-PSMA PET/CT {#Sec9}
------------------

^68^Ga-PSMA PET/CT was rated as negative in 21 patients (46.7 %) and positive in 24 (53.3 %). Among these 24 patients, lesions were only detected on ^68^Ga-PSMA PET in 15 (62.5 %) and only on CT in one (4.2 %). In three patients (12.5 %), ^68^Ga-PSMA PET detected more lesions than CT while in the remaining five patients (20.8 %) results from ^68^Ga-PSMA PET and CT were identical. The mean overall SUV~max~ of PET-positive lesions was 16.24 ± 16.97 (range 3.42--93.29), 18.26 ± 14.71 (range 4.22--58.43) in patients receiving low-dose CT, and 13.52 ± 19.67 (range 3.42--93.29) in patients with contrast-enhanced CT. The mean PSA level was 0.75 ± 0.65 ng/ml (range 0.10--2.80 ng/ml; median 0.57 ng/ml) in ^68^Ga-PSMA PET/CT-negative patients and 1.78 ± 2.69 ng/ml (range 0.12--11.22 ng/ml; median 0.70 ng/ml) in ^68^Ga-PSMA PET/CT-positive patients.

Positive ^68^Ga-PSMA PET/CT results were found in all groups according to the D'Amico risk classification. Lesion types and numbers identified on ^68^Ga-PSMA PET/CT are presented in Table [2](#Tab2){ref-type="table"}. Local recurrence was present in 11 of the 45 patients (24.4 %). Eight patients (17.7 %) had only LNMs; one (2.2 %) had local recurrence and pelvic LNMs (\<5 lesions) detected only on ^68^Ga-PSMA PET; two (4.4 %) had a local recurrence, pelvic LNM, and bone metastases; and two (4.4 %) had rectal lesions suspicious for metastases.Table 2Regions involved due to ^68^Ga-PSMA PET/CTNo. of patients (%)Suspicious lesions detected by CT, PET, or both (%)Only CT positiveOnly PET positiveMore lesions in PETPositive in CT and PETNegative21 (46.7)--------Loc rec11 (24.4)1 (9.0)5 (45.5)--5 (45.5)LNM8 (17.7)--7 (87.5)1 (12.5)-- LNMp (\<5 lesions)6 LNMp + r (\<5 lesions)1 LNMp + r (\>5 lesions)1Loc rec + LNMp (\<5 lesions)1 (2.2)--1 (100)----Loc rec + LNMp + bone2 (4.4)----2 (100)--  \< 5 lesions1  \> 5 lesions1Soft tissue metastasis (rectal)2 (4.4)--2 (100)----SUV~max~ of PET positive lesions: mean 16.24 ± 16.97 (range 3.42--93.29)*Loc rec* local recurrence, *LNM* lymph node metastases, *p* pelvic, *r* retoperitoneal, *bone* bone metastases

Treatment decision {#Sec10}
------------------

The interdisciplinary panel confirmed the intended SRT of the prostate bed in 26 of the 45 patients (57.8 %) and changed the treatment recommendation in the remaining 19 (42.2 %) due to findings on ^68^Ga-PSMA PET/CT (Table [3](#Tab3){ref-type="table"}). In 6/19 patients (31.6 %), a dose escalation was administered due to morphological local recurrence. One of these patients received brachytherapy to avoid side effects to a previously constructed neo-bladder. In 2/19 (10.5 %) patients, the RT field was extended due to a suspicious rectal lesion (without and in combination with surgical resection). In 8/19 (42.1 %) patients, SRT was extended to pelvic and/or retroperitoneal LNMs including dose escalation for involved lymph nodes (Fig. [1](#Fig1){ref-type="fig"}). In 1/19 (5.3 %) patients, SRT was extended to LNMs and a single bone metastasis. In 2/19 (10.5 %) patients with multiple distant metastases (bone) and/or multiple LNMs, the panel recommended systemic treatment with ADT (Fig. [2](#Fig2){ref-type="fig"}). No patient undergoing SRT received ADT.Table 3Treatment recommendations of the panel and follow-up of patientsNo. of patients (*n* = 45)No. of patients following treatment recommendation (*n* = 38)No. of patients with follow-up available (*n* = 22)Confirmed SRT of the prostate bed26/4519/2613/19Treatment changed19/4519/199/19 Dose escalation RT666  • To mLoc rec• 5• 5• 2  • Brachytherapy of mLoc rec• 1• 1• -- SRT extended to LN, including boost88^b^5 SRT extended to rectal wall11^c^-- SRT to LN and single bone metastasis11-- Multimodal concept^a^111 ADT221^d^*mLoc rec* morphological local recurrence, *LN* lymph nodes^**a**^Surgery of rectal soft tissue metastasis, SRT of prostate bed, and RT to rectal wall metastasis (due to R2 resection of metastasis)^**b**^Therapy was canceled in two patients due to rising PSA levels during RT^**c**^Therapy was canceled due to rising PSA levels^**d**^Not included in follow-up calculations Fig. 1A 74-year-old patient with biochemical recurrence (PSA 0.82 ng/ml; pT2aN0cM0; Gleason 6; iPSA 5.37 ng/ml) 8.4 months after radical prostatectomy and lymph node dissection. ^68^Ga-PSMA PET/CT prior to salvage radiotherapy showed two PSMA-positive presacral (**a**, **c**) and retroperitoneal (**b**, **d**) LNMs. Salvage radiotherapy was extended to pelvic lymph nodes, including a dose escalation to the PSMA-positive lymph nodes. The patient was treated with IMRT (**c**, **d** IMRT plan). *red* PTV including pelvic lymph nodes (50.4 Gy), *blue* simultaneous and sequential boost (66 Gy) for iliac (**d**) and presacral (**c**) LNM. RT to prostate bed is not shown. The PSA level decreased to 0.02 ng/ml after SRT Fig. 2A 62-year-old patient with persisting PSA level (0.7 ng/ml) after radical prostatectomy. Initial PSA level 9.24 ng/ml. High-risk (G3) prostate cancer pT3aN1. ^68^Ga-PSMA PET/CT detected multiple small pelvic and retroperitoneal (*arrow*) LNMs. The intended treatment was changed to ADT

Treatment and follow-up {#Sec11}
-----------------------

Overall, 15.6 % (7/45) of the patients did not follow the treatment regimen recommended by the panel. These patients were excluded from follow-up. Of the 38 patients who followed the treatment recommendation, two (5.6 %) started with ADT and 36 (94.7 %) received SRT alone (35 pts) or in combination with a multimodal therapeutic concept (1 pt). SRT was performed between September 2014 and June 2016. Five patients have not finished the treatment at the time of data analysis. One patient receiving SRT of the prostate bed and one patient receiving an additional boost to a presacral LNM suffered from gastrointestinal toxicity grade 2. In three patients, SRT had to be terminated due to rising PSA levels despite treatment.

Follow-up was available in 21/36 (58.3 %) patients undergoing the recommended SRT approach and finishing SRT (Table [3](#Tab3){ref-type="table"}). Mean follow-up was 8.12 ± 5.23 months (range 1.15--24.36 months; median 6.92 months) using the latest available PSA level. Mean pretherapeutic PSA level in these patients was 0.92 ± 0.89 ng/ml (range 0.10--3.51 ng/ml; median 0.60 ng/ml) and mean post-therapeutic PSA level, 0.34 ± 0.67 ng/ml (range \<0.02--2.42 ng/ml; median 0.08 ng/ml). One patient showed a 140 % increase in the pretherapeutic PSA value during post-therapeutic follow-up. PSA values decreased in 20/21 (95.3 %) patients. Mean PSA decline was 78 ± 19 % (range 40--100 %). Post-RT PSA was significantly lower (*p* \< 0.01) than pre-RT PSA levels.

Discussion {#Sec12}
==========

Our data demonstrate that ^68^Ga-PSMA PET/CT impacted treatment in 42.2 % (19/45) of patients.

The concept of automatically combining SRT of the prostate bed with radiation of pelvic lymph nodes as part of SRT is controversial \[[@CR5], [@CR6], [@CR36]\]. In the present cohort, seven patients (15.6 %) had LNMs limited to the pelvis and would have potentially benefited from extended SRT. Interestingly, according to clinical risk stratifications for identification of patients with high risk of LNMs \[[@CR37]\] and therefore suitable for extended irradiation to the pelvic lymph nodes, only five of these seven patients qualified. Moreover, six patients (13.3 %) scheduled for SRT would not have benefited from radiation to the prostate bed and a general extension of SRT to pelvic lymph nodes as they had extrapelvic disease (rectal soft tissue lesions, retroperitoneal LNMs, and/or bone metastases). These data underline the clinical impact of pretherapeutic ^68^Ga-PSMA PET/CT on selection of the most suitable therapeutic approach.

Up to now, only limited data are available on the impact of ^68^Ga-PSMA PET/CT on RT planning \[[@CR28]--[@CR30]\]. Changes in treatment due to ^68^Ga-PSMA PET/CT prior to RT have been reported in previous studies; however, the reported rates were higher compared with our results \[[@CR29], [@CR30]\]. Shakespeare found an alteration of treatment in 53.7 % of patients due to ^68^Ga-PSMA PET/CT performed in addition to conventional imaging \[[@CR29]\]. This study included an inhomogeneous group of 54 patients including some with PSA relapse after definitive or post-prostatectomy RT and some in whom curative doses of RT were planned (definitive or post-prostatectomy) \[[@CR29]\]. Sterzing et al. reported an alteration in the therapeutic approach in 29 (50.8 %) of a cohort of 57 patients with primary and recurrent prostate cancer \[[@CR28]\]. Of these patients, 62.1 % received a boost to pelvic LNMs, while in 27.5 %, the irradiation field was extended to retroperitoneal LNMs and 13.8 % received a systemic treatment \[[@CR28]\]. A radiation boost to PET-positive lesions seems to be justified due to the high PPV of ^68^Ga-PSMA PET/CT \[[@CR28]\]. However, it is crucial to exclude false-positive interpretations due to PSMA-positive celiac ganglia \[[@CR38]\].

Pretherapeutic imaging is gaining importance with the emergence of individualized treatment strategies to replace the use of systemic therapies such as ADT for the treatment of all patients with metastatic disease irrespective of the disease extent, thereby avoiding the latter's various side effects \[[@CR29], [@CR31], [@CR39], [@CR40]\]. In the present study, patients with oligometastatic disease (≤5 lesions) were treated with SRT guided by ^68^Ga-PSMA PET/CT. Recently published studies have limited the number of metastases to ≤3 lesions \[[@CR34], [@CR40]\]. A consistent definition of the oligometastatic tumor stage is warranted for future trials to allow for comparison of results. The strategy of metastasis-directed treatment in the management of prostate cancer patients with oligometastatic disease as an individualized therapeutic approach is still controversial. Oligometastatic disease seems to be an intermediate and unique clinical state in prostate cancer \[[@CR40]\]. Patients with oligometastatic disease may have a superior survival rate \[[@CR41], [@CR42]\] and may benefit from metastasis-directed treatment, with delayed clinical progression and postponement of systemic therapy or even cure \[[@CR34], [@CR40]\]. Pretherapeutic imaging with a high accuracy is crucial to the use of these novel salvage strategies. Molecular imaging has been found to outperform conventional imaging for assessment of disease extent in cases of BCR \[[@CR11], [@CR12], [@CR14], [@CR15]\]. Picchio et al. reported that ^11^C-choline PET/CT is a valuable tool for guidance of RT of ^11^C-choline-positive LNMs and that PET/CT-guided RT resulted in a high early biochemical response rate \[[@CR39]\]. Casamassima et al. reported a 3-year local control rate of 90 % in 25 patients treated with RT for LNMs \[[@CR43]\]. However, previous studies and meta-analyses reported that choline PET/CT offers a low detection rate in patients with early BCR \[[@CR14], [@CR16], [@CR44], [@CR45]\], i.e., the patient cohort recommended for SRT \[[@CR5], [@CR7], [@CR8]\]. ^68^Ga-PSMA PET/CT, on the other hand, has been reported to achieve high detection rates, superior to those of choline PET/CT, even in patients with low PSA levels \[[@CR20]--[@CR24]\]. In addition, it has been found that more lesions with a higher SUV~max~ and tumor-to-background ratio are detected by ^68^Ga-PSMA PET/CT compared with choline PET/CT \[[@CR21], [@CR46]\]. Therefore, ^68^Ga-PSMA PET/CT is regarded as the preferred method for guidance of RT, particularly in patients with low PSA values \[[@CR47]\].

In our total patient cohort, ^68^Ga-PSMA PET/CT-based treatment resulted in biochemical response in all but one patient. PSA values significantly decreased by 78 % compared with pretherapeutic PSA levels. Five of nine patients were treated with a dose escalation to PET-positive LNMs and/or bone metastases using an IMRT technique (oligometastatic concept); the PSA level decreased on average to 15 % of pretherapeutic values. However, three patients had not completed RT as the PSA level was rising during therapy, indicating disease progression, and in one patient, no follow-up was available. Recently, Henkenberens et al. \[[@CR31]\] also reported a significant decrease in PSA values in 29 patients followed up for a similar period and also treated according to an oligometastatic concept. ^68^Ga-PSMA PET/CT seems to be a highly sensitive method for detection of oligometastatic disease and guidance of metastasis-directed treatment; however, the oligometastatic concept has to be investigated in further studies.

The current study has several limitations: First, the analysis is a retrospective analysis of consecutive patients referred for ^68^Ga-PSMA PET/CT prior to SRT. Thus, referral bias cannot be excluded. The highly selected nature of the cohort may be the reason for the relatively low detection rate (53.3 %) compared with previous studies investigating ^68^Ga-PSMA PET/CT in large patient cohorts with BCR (74.2--89.5 %) \[[@CR20], [@CR23], [@CR24]\] or prior to radiotherapy (73.5 and 96.6 %) \[[@CR30], [@CR31]\]. Second, the number of included patients is low, but it is within the range of or superior to the size of patient populations in previously published studies. Third, to date, no long-term follow-up is available for the patients. Fourth, the reason for the treatment failure with increasing post-therapeutic PSA levels in one patient could not be assessed as the patient refused further imaging. Fifth, no histopathological confirmation was available in the present study; however, only few studies are available with histopathologic correlation of the results of ^68^Ga-PSMA PET/CT \[[@CR27]\]. Thus, only limited knowledge about the negative predictive value of ^68^Ga-PSMA PET/CT is available. In the present study, also, patients without any PSMA-positive lesion responded to SRT with decreasing PSA values suggesting small lesions may be missed by ^68^Ga-PSMA PET/CT.

Conclusions {#Sec13}
===========

^68^Ga-PSMA PET/CT impacts treatment planning in more than 40 % of patients scheduled to undergo SRT in the presence of PSA persistence or biochemical relapse after prior radical surgery. Future prospective studies are needed to confirm this significant therapeutic impact on patients prior to SRT.
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